Journal: Drug Design, Development and Therapy

Article Title: 17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway

doi: 10.2147/DDDT.S524747

Figure Lengend Snippet: 17(R)-RvD1 decreases serum uric acid, XOD, ALT and AST levels in hyperuricemia mice. ( A ) Experimental scheme: PO and hypoxanthine were injected intraperitoneally once a day, 17(R)-RvD1 was administered intraperitoneally every other day after modeling. The mice were euthanized on day 21 for subsequent analysis. ( B ) Uric acid, ( C ) XOD, ( D ) ALT and ( E ) AST levels in mice serum.

Article Snippet: 17(R)-RvD1, potassium oxonate, hypoxanthine, uric acid and LPS were purchased from MCE, without additional purification.

Techniques: Injection

Journal: Drug Design, Development and Therapy

Article Title: 17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway

doi: 10.2147/DDDT.S524747

Figure Lengend Snippet: Effects of 17(R)-RvD1 on serum inflammatory cytokines levels in hyperuricemia mice. ( A ) IL-1β levels in mice serum detected by ELISA kit. ( B ) TNF-α levels in mice serum detected by ELISA kit. ( C ) IL-6 levels in mice serum detected by ELISA kit. ( D ) IL-18 levels in mice serum detected by ELISA kit.

Article Snippet: 17(R)-RvD1, potassium oxonate, hypoxanthine, uric acid and LPS were purchased from MCE, without additional purification.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Drug Design, Development and Therapy

Article Title: 17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway

doi: 10.2147/DDDT.S524747

Figure Lengend Snippet: 17(R)-RvD1 reduces hepatic inflammatory cytokines levels in hyperuricemia mice. ( A ) Histological analysis of liver tissues in mice. Scale bar 50 μm. ( B ) NAFLD activity score of livers in mice. ( C ) NLRP3 mRNA expression levels of livers in mice. ( D ) ASC mRNA expression levels of livers in mice. ( E ) Caspase-1 mRNA expression levels of livers in mice. ( F ) Hepatic c-caspase-1 levels in mice detected using ELISA kit. ( G ) Hepatic IL-1β levels in mice detected using ELISA kit. ( H ) Hepatic IL-18 levels in mice detected using ELISA kit.

Article Snippet: 17(R)-RvD1, potassium oxonate, hypoxanthine, uric acid and LPS were purchased from MCE, without additional purification.

Techniques: Activity Assay, Expressing, Enzyme-linked Immunosorbent Assay

Journal: Drug Design, Development and Therapy

Article Title: 17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway

doi: 10.2147/DDDT.S524747

Figure Lengend Snippet: 17(R)-RvD1 improves uric acid-induced hepatocyte pyroptosis in LO2 cells. ( A ) Cell viability of LO2 cells. ( B ) LDH release of LO2 cells. ( C ) NLRP3 mRNA expression levels in LO2 cells. ( D ) ASC mRNA expression levels in LO2 cells. ( E ) Caspase-1 mRNA expression levels in LO2 cells. ( F ) GSDMD levels in LO2 cells measured using immunofluorescence. Scale bar 50 μm. ( G ) C-caspase-1 levels in LO2 cells measured using ELISA kit. ( H ) IL-1β levels in LO2 cells measured using ELISA kit. ( I ) IL-18 levels in LO2 cells measured using ELISA kit.

Article Snippet: 17(R)-RvD1, potassium oxonate, hypoxanthine, uric acid and LPS were purchased from MCE, without additional purification.

Techniques: Expressing, Immunofluorescence, Enzyme-linked Immunosorbent Assay

Journal: Drug Design, Development and Therapy

Article Title: 17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway

doi: 10.2147/DDDT.S524747

Figure Lengend Snippet: 17(R)-RvD1 regulates LO2 cells pyroptosis by inhibiting NF-κB signaling pathway. ( A ) C-caspase-1 levels in LO2 cells exposed to uric acid following treatment with 17(R)-RvD1 or BAY 11–7082. ( B ) IL-1β levels in LO2 cells exposed to uric acid following treatment with 17(R)-RvD1 or BAY 11–7082. ( C ) IL-18 levels in LO2 cells exposed to uric acid following treatment with 17(R)-RvD1 or BAY 11–7082. ( D ) Representative Western blot images were shown on the left, graphic quantification of relative p-NF-κB p65 normalized to NF-κB p65 was shown on the right. ( E ) C-caspase-1 levels in LO2 cells exposed to uric acid following co-treatment with 17(R)-RvD1 and BAY 11–7082. ( F ) IL-1β levels in LO2 cells exposed to uric acid following co-treatment with 17(R)-RvD1 and BAY 11–7082. ( G ) IL-18 levels in LO2 cells exposed to uric acid following co-treatment with 17(R)-RvD1 and BAY 11–7082. ( H ) The speculative mechanism diagram of how 17(R)-RvD1 attenuates liver injury in hyperuricemia created using BioRender.

Article Snippet: 17(R)-RvD1, potassium oxonate, hypoxanthine, uric acid and LPS were purchased from MCE, without additional purification.

Techniques: Western Blot

Journal: Journal of Neuroinflammation

Article Title: P2X7-CaMKII drives 5-LOX nuclear translocation to impair microglial function after subarachnoid hemorrhage

doi: 10.1186/s12974-025-03530-3

Figure Lengend Snippet: 5-LOX subcellular localization is a crucial factor influencing microglial function after SAH. A qPCR detection of inflammatory factors IL-1β, IL-6 and TNF-α after Zileuton intervention; B Flow cytometry detection of the mean fluorescence intensity of pHrodo after Zileuton intervention, and calculation of the phagocytic index; C WB detection of 5-LOX nuclear/cytoplasmic ratio in microglia after Zileuton intervention; D IF detection of the relative mean fluorescence intensity of 5-LOX in the nucleus after Zileuton intervention, bar = 20 μm; E Different subcellular localization of 5-LOX produces different metabolites; F qPCR detection of the inflammatory factors IL-1β, IL-6, and TNF-α after intervention with RvD1 or LXA4; G Flow cytometry was performed to detect the mean fluorescence intensity of pHrodo after RvD1 or LXA4 intervention, and the phagocytic index was calculated; H WB was performed to detect the nuclear/cytoplasmic protein ratio of 5-LOX after RvD1 intervention in microglia; I IF detection of the relative mean fluorescence intensity of 5-LOX in the nucleus after RvD1 intervention, bar = 20 μm; J ELISA detection of LTB4 content in microglia under different intervention conditions; K ELISA detection of LXA4 content in microglia under different intervention conditions; L LTB4/LXA4 ratio in microglia under different intervention conditions. * p <0.05, ** p <0.01, *** p <0.001, **** p <0.0001

Article Snippet: Zileuton(MedChemExpress, HY-14164, 20μM) [ ], BAPTA MedChemExpress, HY-100,168, 10μM [ ], RvD1 Aladdin, R341442, 25nM [ ], LXA4 Aladdin, L345922, 100nM [ ], JNJ MedChemExpress, HY-101,418, 100nM [ ].

Techniques: Flow Cytometry, Fluorescence, Enzyme-linked Immunosorbent Assay

Journal: Journal of Inflammation Research

Article Title: Decrease of Resolvin D1 and E1 in Patients with Chronic Epilepsy, Implicating Dysfunction of Neuroinflammation Resolution

doi: 10.2147/JIR.S521679

Figure Lengend Snippet: Distribution of the levels of the markers in plasma and CSF among patients (n = 65) and controls (n = 43). ( A ) The differences in resolvins between patients with chronic epilepsy and controls. The levels of RvD1 and RvE1 both in plasma and CSF were lower in epilepsy patients than controls. ( B ) The differences in pro-inflammatory markers between patients with chronic epilepsy and controls. The plasma levels of IL-1β and TNF-α were significantly increased in patients compared to controls, while the CSF levels of IL-1β and IL-6 were significantly higher than controls. No difference was found in the levels of plasma IL-6 and CSF TNF-α between the two groups. *** P < 0.001, ** P < 0.01, * P < 0.05, ns, no statistical difference. Unpaired t -test. Data are shown as mean ± SEM.

Article Snippet: The levels of RvD1 and RvE1 in plasma and CSF of all subjects were measured by human resolvin D1 ELISA kit and human resolvin E1 ELISA kit (Cayman Chemical, USA) according to manufacturer’s instructions, the levels of cytokines including interleukin-1β (IL-1β), IL-6 and tumor necrosis factor-α (TNF-α) in plasma and CSF of patients and controls were analyzed by using ELISA kit (Jianglai Biological, China), following the manufacturer’s instructions.

Techniques: Clinical Proteomics

Journal: Journal of Inflammation Research

Article Title: Decrease of Resolvin D1 and E1 in Patients with Chronic Epilepsy, Implicating Dysfunction of Neuroinflammation Resolution

doi: 10.2147/JIR.S521679

Figure Lengend Snippet: Correlations between resolvins and disease severity, as well as cognitive impairment in patients with chronic epilepsy. The plasma level of RvD1 (R = −0.291, P = 0.019) ( A ), plasma RvE1 (R = −0.301, P = 0.015) ( C ), and CSF RvE1 (R = −0.325, P = 0.008) ( D ) positively correlated with NHS3 scores, while CSF RvD1 (R = −0.129, P = 0.307) ( B ) of patients was not correlated with NHS3 scores. Plasma RvD1 level (R = 0.284, P = 0.022) ( E ) was positively correlated with MMSE scores of epilepsy patients, while CSF RvD1 (R = 0.243, P = 0.051) ( F ), plasma RvE1 (R = 0.071, P = 0.573) ( G ), and CSF RvE1 (R = 0.208, P = 0.097) ( H ) and of patients were not correlated with MMSE scores. Spearman correlation.

Article Snippet: The levels of RvD1 and RvE1 in plasma and CSF of all subjects were measured by human resolvin D1 ELISA kit and human resolvin E1 ELISA kit (Cayman Chemical, USA) according to manufacturer’s instructions, the levels of cytokines including interleukin-1β (IL-1β), IL-6 and tumor necrosis factor-α (TNF-α) in plasma and CSF of patients and controls were analyzed by using ELISA kit (Jianglai Biological, China), following the manufacturer’s instructions.

Techniques: Clinical Proteomics